Dr. Agarwal on Second-Line Therapy Selection in Metastatic RCC

Neeraj Agarwal, MD
Published: Thursday, Jan 03, 2019



Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma (mRCC). 
 
If a patient with mRCC has progressed on a VEGF TKI or immunotherapy, physicians should opt for the most effective second-line or salvage therapy. Many of the therapies that are approved in the second-line setting are also approved for later lines of therapy, notes Agarwal. However, the optimal agent in the second-line setting is cabozantinib (Cabometyx), he adds.
 
Cabozantinib inhibits VEGFR, MET, and AXL kinases. As a monotherapy, cabozantinib is associated with the longest progression-free survival (PFS) in the second-line or third-line setting. The length of PFS is an important factor to consider, explains Agarwal. The longer PFS a patient has, the greater the likelihood that they will live and potentially see subsequent lines of therapy, he concludes.
SELECTED
LANGUAGE


Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma (mRCC). 
 
If a patient with mRCC has progressed on a VEGF TKI or immunotherapy, physicians should opt for the most effective second-line or salvage therapy. Many of the therapies that are approved in the second-line setting are also approved for later lines of therapy, notes Agarwal. However, the optimal agent in the second-line setting is cabozantinib (Cabometyx), he adds.
 
Cabozantinib inhibits VEGFR, MET, and AXL kinases. As a monotherapy, cabozantinib is associated with the longest progression-free survival (PFS) in the second-line or third-line setting. The length of PFS is an important factor to consider, explains Agarwal. The longer PFS a patient has, the greater the likelihood that they will live and potentially see subsequent lines of therapy, he concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x